Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.35 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CASP1 | P29466 | 2/20 | 0.33 |
| ▸ | CASP7 | P55210 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771969 | 0.96 | LMNA (0.39) | CA12CA9POLBPIM1LMNA | |
| SCHEMBL5892600 | 0.84 | LMNA (0.47) | CA12CA9POLBPIM1LMNA | |
| SCHEMBL5773746 | 0.78 | ALDH1A1 (0.43) | POLBLMNAHTTKDM4EALDH1A1 | |
| SCHEMBL16708129 | 0.70 | MAOB (0.43) | PIM1LMNAHTTALDH1A1MAPT | |
| SCHEMBL16708178 | 0.69 | PIM1 (0.72) | PIM1LMNAALDH1A1GAAMAPT | |
| SCHEMBL15349582 | 0.69 | LMNA (0.49) | CA12CA9PIM1LMNAHTT | |
| SCHEMBL16710650 | 0.68 | PIM1 (0.43) | PIM1LMNAHTTALDH1A1MAPT | |
| SCHEMBL219330 | 0.67 | LMNA (0.69) | CA12CA9POLBLMNAHTT | |
| SCHEMBL15349740 | 0.65 | LMNA (0.51) | CA12CA9LMNAADORA3ADORA2A | |
| SCHEMBL15359351 | 0.64 | PIM1 (0.40) | CA9PIM1LMNAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | claimed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | claimed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | claimed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | claimed |
| US-7078541-B2 | Benzofuran derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1472241-A4 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS INC (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005027900-A1 | BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1472241-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | Galileo Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040063975-A1 | Benzofuran derivatives | EDISON PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | disclosed |
| US-6653346-B1 | Amtiischemic and antiinflammatory agents | GALILEO PHARMACEUTICALS, INC. | 2003-11-25 | — | — | US | disclosed |
| WO-2003066618-A1 | CYTOPROTECTIVE BENZOFURAN DERIVATIVES | GALILEO PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063975-A1 | Benzofuran derivatives | NDUFAB1, AIFM1, NDUFAF1 | CA12 4872/4885CA9 4869/4885POLB 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.